Tablets & Capsules


Issue link:

Contents of this Issue


Page 7 of 67

6 January/February 2021 Tablets & Capsules markets Softgel capsule market to grow 5.9 percent annually through 2027 SEATTLE, WA—The global soft- gel capsule market is projected to reach $874.35 billion by 2027, grow- ing at a compound annual rate of 5.9 percent, according to a report by Coherent Market Insights. The increasing prevalence of heart con- ditions is expected to drive market growth. Major players in the soft- gel capsule market include Catalent, Aenova Group, Sirio Pharma, Captek Softgel International, Elnova Pharma, Fuji Capsule, Capsugel, EuroCaps, G u a n g d o n g Y i c h a o B i o l o g i c a l , Hunan Er-Kang Pharmaceutical, and KD Pharma Group. Pharmaceutical drug delivery market to grow 4.6 percent DUBLIN, Ireland—The pharma- ceutical drug delivery market is fore- cast to grow at a compound annual rate of 4.6 percent through 2026, according to a report by Research and Markets. North America holds a significant market share due to gov- ernment initiatives for drug delivery technology development, increasing pharmaceutical investment to treat the rising incidence of cancer, and advanced oral drug delivery tech- nologies in the region. The report profiles several companies, including F. Hoffman-La Roche, Bayer, Pfizer, GlaxoSmithKline, Novartis, 3M, Becton, Dickinson and Company, Sanofi, Merck, Antares Pharma, Abb- Vie, Amgen, Johnson & Johnson, AstraZeneca, Eli Lilly and Company, Gilead Sciences, Teva Pharmaceu- ticals, Boehringer Ingelheim, Bris- tol-Myers Squibb, and Genmab. industry news FDA issues guidances on oral contraceptives and proprietary naming for drugs SILVER SPRING, MD—The FDA issued the draft guidance "Clin- ical Drug Interaction Studies with Combined Oral Contraceptives," intended to assist sponsors of inves- tigational new drug applications and new drug applications during drug development in evaluating the need for and design of drug-drug interac- tion (DDI) studies involving com- bined oral contraceptives (COCs). The document discusses when drug developers should conduct DDI stud- ies with COCs, provides recommen- dations on the design and conduct of DDI studies, and how to interpret and communicate the results and rec- ommendations from these studies. The agency also issued two guid- ances on best practices for develop- ing proprietary names for human pre- scription and nonprescription drugs. The documents are intended to help guide sponsors on the development of proposed proprietary names, help minimize name-related medication errors, and avoid adoption of pro- prietary names that violate the Food, Ackley isl 4C Tablet, Capsule and Softgel Printing, Laser Marking & Drilling M A C H I N E S & A C C E S S O R I E S M A C H I N E S & A C C E S S O R I E S Contact Us for a Free Product Evaluation! +1(856)234-3626

Articles in this issue

Links on this page

Archives of this issue

view archives of Tablets & Capsules - TC0121